It has been found that expression of 15-lipoxygenase-1 (15-LOX-1) and its main product, 13-S-hydroxyoctadecadienoic acid (13-S-HODE), are decreased in human colorectal and esophageal cancers and that non-steroidal anti-inflammatory drugs (NSAIDs) can therapeutically induce 15-LOX-1 expression to trigger apoptosis in those cancer cells. We found that a specific cyclooxygenase-2 (COX-2) inhibitor SC-236 similarly induced apoptosis in gastric cancer cells. In the present study, we tested whether SC-236 induced apoptosis through up-regulation of 15-LOX-1 in gastric cancer. 
Introduction
Apoptosis is an essential process for the development and tissue homeostasis of most organisms. Dysregulation of apoptosis, e.g. through bcl-2 expression, has been implicated in the pathogenesis of many diseases including gastric cancer (1) . Accumulating evidence shows that apoptosis plays an important role in the chemopreventive effect of non-steroidal anti-inflammatory drugs (NSAIDs) in human gastric and colon cancer (2) (3) (4) (5) (6) (7) . Initially, the enzyme cyclooxygenase-2 (COX-2) and its inhibition were thought to be major, if not the only, target and mechanism of NSAIDs in carcinogenesis of colorectal and other tumors. It is now understood that other molecular targets besides COX-2 are involved. NSAIDs can trigger apoptosis through down-regulation of peroxisome proliferator-activated receptor gamma (PPAR-γ) (8) . We have reported previously that aspirin and indomethacin induce apoptosis in gastric cancer through up-regulation of bax and bak (9) , and this process is blocked by protein kinase C (PKC) activation through inhibition of c-myc (10) . Overexpression of Abbreviations: COX, cyclooxygenase; HETE, hydroxyeicosatetraenoic acids; HODE, hydroxyoctadecadienoic acid; 15-LOX, 15-lipoxygenase; NSAIDs, non-steroidal anti-inflammatory drugs.
PKC-β1 isoenzyme suppresses indomethacin-induced apoptosis in gastric cancer (11) . Because COX-2 is inducible and often overexpressed in human cancers including colon and gastric cancers (12) , specific COX-2 inhibitors are developed to overcome the side-effect of non-specific inhibitors of the COXs, which can induce apoptosis in human cancer cells through COX-2-dependent and -independent pathways (13) (14) (15) .
NSAIDs can alter the production of different metabolites of polyunsaturated fatty acids (e.g. linoleic acid and arachidonic acid) by modulating the activity of lipoxygenases (LOXs) and COXs (16) . In the classic pathway involving only arachidonic acid (the eicosanoid-generation pathway), arachidonic acid is a substrate for both LOX and COX enzymes to form various metabolites, such as 5-, 8-, 12-and 15-S-hydroxyeicosatetraenoic acids (HETEs) and prostaglandins (17) . However, linoleic acid, the predominant polyunsaturated fatty acid in the human diet, can undergo oxidative metabolism, mainly limited to the 15-LOX-1 pathway, which produces 13-S-hydroxy octadecadienoic acid (13-S-HODE) (18) . The expression of 15-LOX-1 is down-regulated in colorectal cancer (19, 20) . Indomethacin treatment decreases the expression of COX-2 and significantly increases the expression of 15-LOX-1 during apoptosis and cell differentiation in sodium butyrate-treated colorectal cancer cells (21) . NSAIDs induce expression of 15-LOX-1 in colorectal and esophageal cancer cells irrespective of COX-2 expression, and up-regulation of 15-LOX-1 is critical to the induction of apoptosis by NSAIDs (22) (23) (24) .
This study is designed to assess whether SC-236, a specific COX-2 inhibitor, induces 15-LOX-1 expression in gastric cancer cells; and whether the effect of SC-236 on apoptosis in gastric cancer cells is mediated through up-regulation of 15-LOX-1.
72 h. The presence of 0.5% DMSO did not affect cell growth in repeated experiments. To further assess whether the effects of 15-LOX-1 inhibition resulted from the loss of 13-S-HODE production, additional experiments were carried out. Gastric cancer cells were treated with SC-236 (50 µM) with and without the addition of caffeic acid (4.4 µM), and then 13-S-HODE (135 µM) or linoleic acid (135 µM) was added, as described previously (23) .
RT-PCR analysis of COX-1 and COX-2 mRNA expression
The expression of COX-1 and COX-2 was detected in various gastric cancer cells (AGS, MGC803, MKN45, MKN28). Cells were harvested and total RNA was extracted using TRIzol Reagent (Gibco BRL). Two micrograms of RNA was reverse transcribed to cDNA by Thermoscript RT system reagent (Gibco BRL) according to manufacturer's instruction. PCR was performed using 2 µl of resulting cDNA, 0.5 U Hotstart DNA polymerase, forward and reverse primers and dNTPs in a final volume of 50 µl. Forward (F) and reverse (R) primers used to detect COX-1 and COX-2 cDNAs in the amplification were: COX1-F, 5Ј-ACTCACGGGCGCTGGTT CTGG-3Ј; COX1-R, 5Ј-CTGGCTCTGGGGCGGGATGC-3Ј; COX2-F, 5Ј-TATA CTA-GAGCCCTTCCTCCTGTGCC-3Ј; and COX2-R, 5Ј-ACATCGCATACTCTG TTGTGTTCCC-3Ј. Hotstart PCR was performed for 35 cycles with 95°C denaturation for 15 min (first cycle), 94°C denaturation for 30 s, 55°C annealing for 45 s, and 72°C elongation for 1 min and 10 min (final cycle). Amplification products for COX-1 and COX-2 were of the expected sizes (574 and 503 bp, respectively).
MTT assay
Cell proliferation was measured by MTT assay. Exponentially growing cells were plated into 96 well plates containing 5000 cells/well in 200 µl medium for 24 h. Then cells were treated with different concentrations of SC-236 for 24, 48 and 72 h. Twenty microliters of MTT stock solution (5 mg/ml) was added into each well, and cells were further incubated at 37°C for 4 h. The supernatant was replaced with 200 µl isopropanol to dissolve formazan production. The absorbance at wavelength 595 nm was measured with a micro-ELISA reader (Bio-Rad, Hercules, CA). The negative control well, into which only the medium had been added, was used for zeroing the absorbance. Each assay was performed three times in triplicate. The ratio of the absorbance of treated cells relative to that of the control cells were calculated and expressed as percentage of growth inhibition.
Semi-quantitative RT-PCR analysis of 15-LOX-1 mRNA expression
Total RNA was isolated from AGS and MGC803 cells after treatment with and without SC-236 for 12, 24, 48 and 72 h. Two micrograms of RNA was reverse transcribed to cDNA. PCR was performed using 2 µl of resulting cDNA, 0.5 U Hotstart DNA polymerase, reverse and forward primers and dNTPs in a final volume of 50 µl. Semi-quantification of 15-LOX-1 mRNA expression was determined by referring to the mRNA expression of a housekeeping gene, GAPDH. For amplification of the human 15-LOX-1 and GAPDH, the forward and reverse primer combinations were designed according to previous publication, 5Ј-GCTGCGGCTCTGGGAAATCATCT-3Ј and 5Ј-GGGCCCGAAAAATACTCCTCCTCA-3Ј (15-LOX-1) and 5Ј-GGTGAA-GGTCGGAG TCAACG-3Ј and 5Ј-CAAAGTTGTCATGGATGACC-3Ј (GAP-DH). PCR amplification was linear within the range of 25-40 cycles. PCR products were electrophoretically separated on 1.5% agarose gel, stained with ethidium bromide and visualized under ultraviolet light.
Western blotting analysis AGS and MGC803 were treated with and without SC-236 (50 µM) when reaching 60-80% confluence for 96 h. The cells were extracted with lysis buffer containing protease inhibitors (20 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 1 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride, 0.5% NP-40). The protein concentration was determined by bicinchoninic acid assay with bovine serum albumin (Sigma) as the standard. Equal aliquots of total cell lysates (40 µg) of each sample were solubilized in sample buffer and electrophoresed on 10% SDS-PAGE gel. The proteins were then transferred to polyvinylidene difluoride membranes (Millipore) using transfer buffer for 2 h. Non-specific binding was blocked with 10 mM pH 7.6 Tris-HCl buffer saline plus 0.05% Tween-20 containing 5% skimmed milk for 1 h at room temperature. The blots were probed with primary antibodies overnight at 4°C. The primary antibodies included monoclonal goat anti-human COX-1 antibody (1:1000) and goat anti-human COX-2 antibody (1:1000) (Santa Cruz, CA, USA); polyclonal rabbit anti-human 5-LOX serum (1:500), polyclonal rabbit anti-human 12-LOX (1:500) (Cayman Chemical) and mouse monoclonal mouse anti-human actin antibody (1:1000) (Santa Cruz). Antigen-antibody complexes were visualized by the ECL system.
Immunoassay of endogenous 13-S-HODE and 15-S-HETE production
AGS and MGC803 cells were cultured for 48 h after treatment with SC-236 and then lysed. 13-S-HODE and 15-S-HETE were extracted as described previously (20) . In brief, the cells were homogenized in PBS at 4°C and 244 centrifuged at 2100 g for 2 min. The solution was acidified to a pH of 3.5-4.0 with 0.2 M HCl solution. The organic phase of the solution was extracted with water-saturated ethyl acetate. Samples were dried completely in a centrifuge dryer, and reconstituted with dilution buffer (provided with the kits). Levels of 13-S-HODE and 15-S-HETE were measured according to the manufacturer's protocol.
Apoptosis assays
Apoptosis was quantitatively evaluated by acridine orange staining examination to identify morphological changes. Single-cell suspensions were fixed in 1% formalin/PBS and stained with acridine orange (10 µg/ml, Sigma). A drop of the stained cell suspension was placed on a microscope slide. Cells were visualized under fluorescence microscope with blue-green filter. The apoptotic cells were defined as cells showing cytoplasmic and nuclear shrinkage and chromatin condensation or fragmentation. At least 300 cells were counted, and the percentage of apoptotic cells was determined.
In addition, cells were harvested 72 h after treatment and then lysed. DNA was extracted from an equal number of cells, precipitated, electrophoresed on a 1% agarose gel, and examined after being stained with ethidium bromide, as described previously (25) .
Statistical analyses
All experiments were performed in triplicate and were repeated at least three times. Mean values Ϯ SEM were calculated to represent the three experiments. Statistical difference was determined by Student's t-test, or one-way ANOVA. A P value of Ͻ0.05 was considered significant.
Results

COX-1 and COX-2 mRNA expression in gastric cancer cells
COX-1 and COX-2 expression at the mRNA level were examined by RT-PCR analysis in the four gastric cancer cell lines, AGS, MGC803, MKN28 and MKN45. COX-1 mRNA was expressed constitutively in all four cell lines ( Figure 1A ). COX-2 mRNA was expressed in AGS, MKN28 and MKN45 cells, but had a low expression in MGC803 cells ( Figure 1B) .
Effect of SC-236 on growth of AGS and MGC803
To evaluate the effect of SC-236 on the growth of AGS and MGC803, SC-236 at various concentrations were added to the culture medium for 24, 48 and 72 h. MTT assay showed that SC-236 inhibited cell growth in a time-dependent manner in both AGS (Figure 2A ) and MGC803 ( Figure 2B ) cells when SC-236 was added at a concentration of 25 µM or higher (all P Ͻ 0.05, one-way ANOVA). Moreover, there was also a dose-dependent inhibitory effect (all P Ͻ 0.05, one-way ANOVA). Compared with the control, significant inhibition of cell growth was observed for both cell lines 48 h after SC-236 at concentrations of 50 and 100 µM (all P Ͻ 0.05). The concentration of SC-236 for further experiments was chosen at 50 µM based on the MTT assay results. 
Effect of SC-236 on COX-1, COX-2, 5-LOX and 12-LOX protein expression
To investigate the effect of SC-236 on other arachidonic acid metabolites, we examined the expression of COX-1, COX-2, 5-LOX and 12-LOX proteins in both AGS and MGC803 cells at different time intervals. Western blots showed that COX-1, COX-2, 5-LOX and 12-LOX protein expression remained unchanged after SC-236 treatment at the concentration of 50 µM for up to 72 h (Figure 4) .
Effect of SC-236 on 13-S-HODE and 15-S-HETE production
Endogenous 13-S-HODE was below detectable levels in untreated cells ( Figure 5 ). SC-236 (50 µM) increased endogenous 13-S-HODE to 8.69 Ϯ 1.07 and 13.15 Ϯ 4.52 (ng/µg protein) in AGS and MGC803 cells, respectively, after treatment for 48 h ( Figure 5 ). Addition of caffeic acid (4.4 µM), which is a specific inhibitor of 15-LOX-1, did not affect the basal level of 13-HODE, but suppressed SC-236-induced production of 13-S-HODE. On the other hand, 15-S-HETE was undetectable with or without SC-236 treatment in AGS and MGC803 cells (data not shown).
Apoptosis induced by SC-236 and reversed by caffeic acid
Quantitative examination by acridine orange staining showed that SC-236 induced apoptosis in a dose-and time-dependent human gastric cancer cell lines tested, suggesting that 15-LOX-1 down-regulation occurs in tumorigenesis. We showed that SC-236 up-regulated 15-LOX-1 expression and increased 13-S-HODE production in gastric cancer cells.
The crucial role of 15-LOX-1 up-regulation in SC236-induced apoptosis was demonstrated by the blockage of apoptosis via inhibition of 15-LOX-1. Because SC236-induced up-regulation of 15-LOX-1 increased the formation of 13-S-HODE but not of 15-S-HETE (the other major product of 15-LOX-1), it is clear that the effects of 15-LOX-1 up-regulation on apoptosis are mediated through 13-S-HODE. These findings agree with previous reports that linoleic acid is the preferred substrate for human 15-LOX-1, which predominantly produces 13-S-HODE (19, 20) . The selective inhibition of the enzymatic activity of 15-LOX-1 with caffeic acid also inhibits formation of 13-S-HODE in gastric cancer cells. This inhibition of 13-S-HODE formation by 15-LOX-1 inhibits apoptosis. More importantly, addition of 13-S-HODE overcomes the block on apoptosis induced by caffeic acid, indicating that 13-S-HODE is the mediator of apoptosis in gastric cancer. Therefore, 15-LOX-1 and 13-S-HODE are the crucial pathways in SC-236-induced apoptosis in gastric cancer cells. The effects observed in SC-236, however, would be regarded as specific to this compound only, and need to be studied in other COX-2 inhibitors to see if it can be generalized.
The mechanism for 15-LOX-1 up-regulation by NSAIDs remains unknown. Regulation of 15-LOX-1 expression has been observed at the transcriptional and post-translational levels (26) . Acetylation by histone acetyltransferase CREBbinding protein/p300 of STAT6 is required for transcriptional activation of the 15-LOX-1 (27) . Interleukin-4 (IL-4) induces expression of 15-LOX-1 in various mammalian cells via STAT6 signaling transduction pathway (27, 28) .
The reported link between 13-S-HODE and peroxisome proliferator-activated receptor-γ activation may be another signal transduction pathway involved in NSAID-induced apoptosis in gastric cancer. 15-LOX-1 metabolites downregulate PPAR-γ via up-regulating MAPK activity and increasing PPAR-γ phosphorylation (29) .
15-LOX-1 is a specific and crucial molecular target for inducing apoptosis, whereas other lipoxygenases block apoptosis and promote cell proliferation through the formation of HETE products, thereby promoting tumorigenesis (30, 31) . We have reported that 12-LOX inhibition induced apoptosis in human gastric cancer cells (32) . Our present study indicated that 15-LOX-1 is up-regulated in NSAID-induced apoptosis. We also showed in gastric cancer cells the unique role of 15-LOX-1 in promoting apoptosis through the production of 13-S-HODE, thus potentially inhibiting tumorigenesis. These results identify novel molecular targets for the study of chemoprevention and treatment of gastric cancer.
